Weight loss drugs and CMS coverage: Why all eyes are on Medicare
(By Rylee Wilson for Becker’s Hospital Review) New GLP-1 drugs to treat diabetes and obesity can be expensive, and most
Read More
Part D/Prescription Drugs
The Facts About Medicare Spending
(Source – The Kaiser Family Foundation Published June 2023) Medicare provides health insurance coverage for more than 65 million people,
Read MoreCDC: Drug costs keep millions from taking medications as prescribed
(By Erica Carbajal for Becker’s Hospital Review) Newly released data from the CDC shows more than 9 million U.S. adults
Read MoreFDA approves Pfizer’s RSV vaccine for older adults
(By Helen Branswell for STAT) The Food and Drug Administration approved a second vaccine to protect older adults against RSV
Read MoreCommercial insurance enrollees pay less for ultra-expensive drugs than Medicare Part D members: Study
(By Rylee Wilson for Becker’s Hospital Review) Medicare Part D beneficiaries that don’t receive low-income subsidies spend 2.5 times more
Read MoreScience finally figured out how to make effective RSV vaccines. Will seniors care?
(By Helen Branswell for STAT) The world has waited decades for vaccines to protect older adults against RSV. One, made
Read MoreHow Medicare’s Aduhelm decision revived old questions about new drugs
(By Kerry Dooley Young for STAT) Medicare’s decision to withhold coverage for Biogen’s Aduhelm despite the Food and Drug Administration’s
Read MoreThis Panel Will Decide Whose Medicine to Make Affordable. Its Choice Will Be Tricky
(By Markian Hawryluk for KFF Health News) Catherine Reitzel’s multiple sclerosis medication costs nearly $100,000 a year. Kris Garcia relies
Read MoreCMS proposes rules to improve Medicaid drug price transparency
(By Rylee Wilson for Becker’s Hospital Review) CMS is proposing a set of rules for drug manufacturers, pharmaceutical benefit managers
Read MoreA More Aggressive FTC Is Starting to Target Drug Mergers and Industry Middlemen
(By Arthur Allen for KFF Health News) Under the leadership of an aggressive opponent of anti-competitive business practices, the Federal
Read More